244 related articles for article (PubMed ID: 29187403)
1. Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery.
Huang HC; Rizvi I; Liu J; Anbil S; Kalra A; Lee H; Baglo Y; Paz N; Hayden D; Pereira S; Pogue BW; Fitzgerald J; Hasan T
Cancer Res; 2018 Jan; 78(2):558-571. PubMed ID: 29187403
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy.
Anbil S; Pigula M; Huang HC; Mallidi S; Broekgaarden M; Baglo Y; De Silva P; Simeone DM; Mino-Kenudson M; Maytin EV; Rizvi I; Hasan T
Mol Cancer Ther; 2020 Jun; 19(6):1308-1319. PubMed ID: 32220968
[TBL] [Abstract][Full Text] [Related]
3. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
Ko AH
Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
[TBL] [Abstract][Full Text] [Related]
6. Chain-Length- and Saturation-Tuned Mechanics of Fluid Nanovesicles Direct Tumor Delivery.
Dai Z; Yu M; Yi X; Wu Z; Tian F; Miao Y; Song W; He S; Ahmad E; Guo S; Zhu C; Zhang X; Li Y; Shi X; Wang R; Gan Y
ACS Nano; 2019 Jul; 13(7):7676-7689. PubMed ID: 31187973
[TBL] [Abstract][Full Text] [Related]
7. Folate receptor-mediated celastrol and irinotecan combination delivery using liposomes for effective chemotherapy.
Soe ZC; Thapa RK; Ou W; Gautam M; Nguyen HT; Jin SG; Ku SK; Oh KT; Choi HG; Yong CS; Kim JO
Colloids Surf B Biointerfaces; 2018 Oct; 170():718-728. PubMed ID: 30005409
[TBL] [Abstract][Full Text] [Related]
8. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
[TBL] [Abstract][Full Text] [Related]
9. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
Chen PY; Ozawa T; Drummond DC; Kalra A; Fitzgerald JB; Kirpotin DB; Wei KC; Butowski N; Prados MD; Berger MS; Forsayeth JR; Bankiewicz K; James CD
Neuro Oncol; 2013 Feb; 15(2):189-97. PubMed ID: 23262509
[TBL] [Abstract][Full Text] [Related]
10. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
11. Minocycline and photodynamic priming significantly improve chemotherapy efficacy in heterotypic spheroids of pancreatic ductal adenocarcinoma.
Bano S; Alburquerque JQ; Roberts HJ; Pang S; Huang HC; Hasan T
J Photochem Photobiol B; 2024 Jun; 255():112910. PubMed ID: 38663337
[TBL] [Abstract][Full Text] [Related]
12. Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study.
Ramanathan RK; Korn RL; Raghunand N; Sachdev JC; Newbold RG; Jameson G; Fetterly GJ; Prey J; Klinz SG; Kim J; Cain J; Hendriks BS; Drummond DC; Bayever E; Fitzgerald JB
Clin Cancer Res; 2017 Jul; 23(14):3638-3648. PubMed ID: 28159813
[No Abstract] [Full Text] [Related]
13. Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery.
Zhan Q; Shen B; Deng X; Chen H; Jin J; Zhang X; Peng C; Li H
Int J Nanomedicine; 2013; 8():2465-72. PubMed ID: 23885173
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract][Full Text] [Related]
15. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
Govindan SV; Cardillo TM; Moon SJ; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2009 Oct; 15(19):6052-61. PubMed ID: 19789330
[TBL] [Abstract][Full Text] [Related]
16. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
[TBL] [Abstract][Full Text] [Related]
19. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
20. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
